Andrews 1976.

Methods	Allocation: randomly assigned. Blinding: double, identical capsules given by the hospital pharmacist who "alone held the key to the drug assignment". Duration: 42 weeks (preceded by 8 weeks stabilisation on chlorpromazine).
Participants	Diagnosis: schizophrenia. N=32. Age: mean 55 yrs. Sex: all male. History: in hospital > 6 yrs, mean 23 yrs, on oral phenothiazine. Excluded: on depot injections of phenothiazine.
Interventions	1. Chlorpromazine cessation: placebo. N=17. 2. Chlorpromazine continuation: dose 50,150‐200 or 200‐450 mg/day. N=15.
Outcomes	Relapse. Unable to use ‐ Behaviour change: WBRSW (no SD). Leaving the study early: due to deterioration of behaviour ‐ 3 people (not reported by group). Death: coronary thrombosis (not reported by group).
Notes	For one patient in the Control Group, the urine test for CPZ was negative and this patient "who did not relapse" was omitted from analysis in the results.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear